Fig. 6.

Sunitinib treatment leads to tumor regression and pSTAT3 reduction within the tumor. Groups of tumor-bearing mice with tumor volume > 123.6 mm³ were administered either sunitinib every other day for two weeks or treated with vehicle. (A) The tumor volume was measured by MRI every month after treatment with sunitinib and the fold-change in tumor volume is shown and (B) Tumor tissue was harvested from the mice treated above, and the proteins were extracted, quantified, and analyzed by Western blotting with antibodies specific for the indicated proteins and β-actin as an internal control. A representative result is shown. Con, vehicle treated mice; SU, sunitinib treated mice